

Faster Cognitive Decline in the Years Prior to Magnetic Resonance Imaging Is Associated With Smaller Hippocampal Volumes in Cognitively Healthy Older Persons

Debra A. Fleischman, PhD; Lei Yu, PhD;
Konstantinos Arfanakis, PhD; S. Duke Han, PhD;
Lisa L. Barnes, PhD; Zoe Arvanitakis, MD, MS;
Patricia A. Boyle, PhD; David A. Bennett, MD

References

1. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer's disease: challenges to early intervention. *Neurology*. 2007;69(16):1622-1634.
2. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer's disease. 2000-2050: potential implication of treatment advances. *Annu Rev Public Health*. 2002;23:213-231.
3. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging and the Alzheimer's Association workgroup on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):257-262.
4. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):280-292.
5. Amieva H, Le Goff M, Millet X, et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms. *Ann Neurol*. 2008;64(5):492-498.
6. Johnson DK, Storandt M, Morris JC, Galvin JE. Longitudinal study of the transition from healthy aging to Alzheimer's disease. *Arch Neurol*. 2009;66(10):1254-1259.
7. Wilson, R.S., Leurgans, S.E., Boyle, P.A., and Bennett, D.A. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. *Arch Neurol*. 2011;68(3):351-356.
8. Wilson RS, Segawa E, Boyle PA, Anagnos SE, Hizek LP, Bennett DA. The natural history of cognitive decline in Alzheimer's disease. *Psychol Aging*. 2012;27(4):1008-1017.
9. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. *Ann Neurol*. 2012;72(4):599-609.
10. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol*. 2010;9(1):119-128.
11. Jack CR Jr, Wiste HJ, Vemuri P, et al; Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. *Brain*. 2010;133(11):3336-3348.
12. Mormino EC, Kluth JT, Madison CM, et al; and the Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated β -amyloid deposition in elderly subjects. *Brain*. 2008;132(pt 5):1310-1323.
13. Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. *Neuroimage*. 2003;18(2):525-541.
14. Mungas D, Reed BR, Jagust WJ, et al. Volumetric MRI predicts rate of cognitive decline related to AD and cerebrovascular disease. *Neurology*. 2002;59(6):867-873.
15. Risacher SL, Shen L, West JD, et al; and the Alzheimer's Disease Neuroimaging Initiative. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. *Neurobiol Aging*. 2010;31(8):401-418.
16. van Rossum IA, Vos SJ, Burns L, et al. Injury markers predict time to dementia in subjects with MCI and amyloid pathology. *Neurology*. 2012;79(17):1809-1816.
17. Du AT, Schuff N, Chao LL, et al. Age effects on atrophy rates of entorhinal cortex and hippocampus. *Neurobiol Aging*. 2006;27(5):733-740.
18. Dickerson BC, Feczko E, Augustinack JC, et al. Differential effects of aging and Alzheimer's disease on medial temporal lobe cortical thickness and surface area. *Neurobiol Aging*. 2009;30(3):432-440.
19. Fjell AM, Westlye LT, Espeseth T, et al. Cortical gray matter atrophy in healthy aging cannot be explained by undetected incipient cognitive disorders: a comment on Burgmans et al. (2009). *Neuropsychology*. 2010;24(2):258-266.
20. Head D, Rodrigue KM, Kennedy KM, Raz N. Neuroanatomical and cognitive mediators of age-related differences in episodic memory. *Neuropsychology*. 2008;22(4):491-507.

21. Mu Q, Xie J, Wen Z, Weng Y, Shuyun Z. A quantitative MR study of the hippocampal formation, the amygdala, and the temporal horn of the lateral ventricle in healthy subjects 40 to 90 years of age. *AJNR Am J Neuroradiol*. 1999;20(2):207-211.
22. Mungas D, Harvey D, Reed BR, et al. Longitudinal volumetric MRI change and rate of cognitive decline. *Neurology*. 2005;65(4):565-571.
23. Raji CA, Lopez OL, Kuller LH, Carmichael OT, Becker JT. Age, Alzheimer disease, and brain structure. *Neurology*. 2009;73(22):1899-1905.
24. Raz N, Lindenberger U, Rodrigue KM, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. *Cereb Cortex*. 2005;15(11):1676-1689.
25. Rosano C, Aizenstein HJ, Newman AB, et al; for the Health ABC Study. Neuroimaging differences between older adults with maintained versus declining cognition over a 10-year period. *Neuroimage*. 2012;62(1):307-313.
26. Tisserand DJ, Visser PJ, van Boxtel MP, Jolles J. The relation between global and limbic brain volumes on MRI and cognitive performance in healthy individuals across the age range. *Neurobiol Aging*. 2000;21(4):569-576.
27. Tupler LA, Krishnan KR, Greenberg DL, et al. Predicting memory decline in normal elderly: genetics, MRI, and cognitive reserve. *Neurobiol Aging*. 2007;28(11):1644-1656.
28. Walhovd KB, Westlye LT, Amlien I, et al. Consistent neuroanatomical age-related volume differences across multiple samples. *Neurobiol Aging*. 2011;32(5):916-932.
29. Allen JS, Bruss J, Brown CK, Damasio H. Normal neuroanatomical variation due to age: the major lobes and a parcellation of the temporal region. *Neurobiol Aging*. 2005;26(9):1245-1260.
30. Fjell AM, Westlye LT, Amlien I, et al. High consistency of regional cortical thinning in aging across multiple samples. *Cereb Cortex*. 2009;19(9):2001-2012.
31. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of ageing in 464 normal adult human brains. *Neuroimage*. 2001;14(1)(pt 1):21-36.
32. Lemaitre H, Goldman AL, Sambataro F, et al. Normal age-related brain morphometric changes: nonuniformity across cortical thickness, surface area and gray matter volume? *Neurobiol Aging*. 2012;33(3):617.e1-617.e9.
33. Lo RY, Hubbard AE, Shaw LM, et al; for the Alzheimer's Disease Neuroimaging Initiative. Longitudinal change of biomarkers in cognitive decline. *Arch Neurol*. 2011;68(10):1257-1266.
34. Raz N, Gunning FM, Head D, et al. Selective aging of the human cerebral cortex observed in vivo: differential vulnerability of the prefrontal gray matter. *Cereb Cortex*. 1997;7(3):268-282.
35. Resnick SM, Pham DL, Kraut MA, Zonderman AB, Davatzikos C. Longitudinal magnetic resonance imaging studies of older adults: a shrinking brain. *J Neurosci*. 2003;23(8):3295-3301.
36. Salat DH, Buckner RL, Snyder AZ, et al. Thinning of the cerebral cortex in aging. *Cereb Cortex*. 2004;14(7):721-730.
37. Van Petten C. Relationship between hippocampal volume and memory ability in healthy individuals across the lifespan: review and meta-analysis. *Neuropsychologia*. 2004;42(10):1394-1413.
38. Hobart J, Cano S, Posner H, et al; for Alzheimer's Disease Neuroimaging Initiative. Putting the Alzheimer's cognitive test to the test, I: traditional psychometric methods. *Alzheimers Dement*. 2013;9(1)(suppl):S4-S9.
39. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the Rush Memory and Aging Project. *Curr Alzheimer Res*. 2012;9(6):646-663.
40. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984;34(7):939-944.
41. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. *Neuron*. 2002;33(3):341-355.
42. Han X, Fischl B. Atlas renormalization for improved brain MR image segmentation across scanner platforms. *IEEE Trans Med Imaging*. 2007;26(4):479-486.
43. SAS Institute Inc. *SAS/STAT® 9.3 User's Guide*. Cary, NC: SAS Institute Inc; 2012.
44. Salthouse, T.A. Neuroanatomical substrates of age-related cognitive decline. *Psychol Bull*. 2011;137(5):753-784.
45. Hertzog C, Kramer AF, Wilson RS, Lindenberger U. Enrichment effects on adult cognitive development: can the functional capacity of older adults be preserved and enhanced? *Psychol Sci Public Interest*. 2009;9(1):1-65.
46. Teng EL, Chui HC. The Modified Mini-Mental State (3MS) examination. *J Clin Psychiatry*. 1987;48(8):314-318.
47. Wilson RS, Li Y, Bienias JL, Bennett DA. Cognitive decline in old age: separating retest effects from the effects of growing older. *Psychol Aging*. 2006;21(4):774-789.
48. Dawe RJ, Bennett DA, Schneider JA, Arfanakis K. Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. *PLoS One*. 2011;6(10):e26286.
49. Burton EJ, Mukaetova-Ladinska EB, Perry RH, Jaros E, Barber R, O'Brien JT. Quantitative neurodegenerative pathology does not explain the degree of hippocampal atrophy on MRI in degenerative dementia. *Intl J Geriatr Psychiatry*. 2012;27(12):1267-1274.
50. Erten-Lyons D, Dodge HH, Woltjer R, et al. Neuropathologic basis of age-associated brain atrophy. *JAMA Neurol*. 2013;70(5):616-622.
51. Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in aging and dementia. *Ann Neurol*. 2008;63(1):72-80.
52. Mueller SG, Stables L, Du AT, et al. Measurement of hippocampal subfield and age-related changes in high resolution MRI at 4T. *Neurobiol Aging*. 2007;28(5):719-726.

Mechanism-Based Treatments in Neurodevelopmental Disorders: Fragile X Syndrome

Elizabeth Berry-Kravis, MD, PhD

References

1. Coffee B, Keith K, Albizua I, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. *Am J Hum Genet.* 2009;85(4):503-514.
2. Willemsen R, Levenga J, Oostra BA. CGG repeat in the FMR1 gene: size matters. *Clin Genet.* 2011;80(3):214-225.
3. Seltzer MM, Baker MW, Hong J, Maenner M, Greenberg J, Mandel D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. *Am J Med Genet B Neuropsychiatr Genet.* 2012;159B(5):589-597.
4. Tassone F, Iong KP, Tong T, et al. FMR1 CGG allele size and expansion prevalence ascertained through newborn screening in the United States. *Genome Med.* 2012;4:100.
5. Hagerman RJ, Berry-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. *J Pediatr.* 2009;123(1):378-390.
6. Berry-Kravis E, Sumis A, Hervey C, Mathur S. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile X syndrome. *Int J Pediatr.* 2012;2012:843016.
7. Wang LW, Berry-Kravis E, Hagerman RJ. Fragile X: leading the way for targeted treatments in autism. *Neurotherapeutics.* 2010;7(3):264-274.
8. Berry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey D. Seizures in fragile X syndrome: characteristics and comorbid diagnoses. *Am J Intellect Dev Disabil.* 2010;115(6):461-472.
9. Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. *Ment Retard Dev Disabil Res Rev.* 2004;10(1):31-41.
10. Bailey DB Jr, Raspa M, Bishop E, Olmsted M, Malya U, Berry-Kravis E. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. *J Dev Behav Pediatr.* 2012;33(1):62-69.
11. The Dutch-Belgian Fragile X Consortium. *Fmr1* knockout mice: a model to study fragile X mental retardation. *Cell.* 1994;78(1):23-33.
12. Grossman AW, Aldridge GM, Weiler IJ, Greenough WT. Local protein synthesis and spine morphogenesis: fragile X syndrome and beyond. *J Neurosci.* 2006;26(27):7151-7155.
13. Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc Natl Acad Sci USA.* 2002;99(11):7746-7750.
14. Berry-Kravis E, Knox A, Hervey C. Targeted treatments for fragile X syndrome. *J Neurodev Disord.* 2011;3(3):193-210.
15. Bagni C, Tassone F, Neri G, Hagerman R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. *J Clin Invest.* 2012;122(12):4314-4322.
16. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. *Trends Neurosci.* 2004;27(7):370-377.
17. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. *Neuropharmacology.* 2005;49(7):1053-1066.
18. de Vrij FM, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in *Fmr1* KO mice. *Neurobiol Dis.* 2008;31(1):127-132.
19. Dölen G, Osterweil E, Shankaranarayana Rao BS, et al. Correction of fragile X syndrome in mice. *Neuron.* 2007;56(6):955-962.
20. McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a model of fragile X syndrome. *Neuron.* 2005;45(5):753-764.
21. Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. *Neuron.* 2012;74(1):49-56.
22. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. *Biochem Pharmacol.* 2010;79(4):632-646.
23. Berry-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. *J Dev Behav Pediatr.* 2008;29(4):293-302.
24. Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. *J Med Genet.* 2009;46(2):94-102.

25. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. *BMC Neurol.* 2010;10:91.
26. Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. *J Dev Behav Pediatr.* 2013;34(3):147-155.
27. Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in *Drosophila*. *Nat Chem Biol.* 2008;4(4):256-263.
28. Pacey LK, Heximer SP, Hampson DR. Increased GABA(B) receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. *Mol Pharmacol.* 2009;76(1):18-24.
29. Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen. *Sci Transl Med.* 2012;4(152):152ra128.
30. Berry-Kravis E, Hessel D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. *Sci Transl Med.* 2012;4(152):152ra127.
31. Maltas S, Widaman KF, Hall S, et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. *J Autism Dev Disord.* 2012;42(7):1377-1392.
32. Erickson CA, Wink LK, Ray B, et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. *Psychopharmacology (Berl).* 2013;228(1):75-84.
33. Berry-Kravis E, Hessel D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. *J Med Genet.* 2009;46(4):266-271.
34. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the *FMR1* gene in fragile X patients leads to a differential response to the mGluR5 antagonist AFQ056. *Sci Trans Med.* 2011;3(64):64ra1.
35. Berry-Kravis E, Hessel D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK; Outcome Measures Working Groups. Outcome measures for clinical trials in fragile X syndrome. *J Dev Behav Pediatr.* 2013;34(7):508-522.
36. Farzin F, Scaggs F, Hervey C, Berry-Kravis E, Hessel D. Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome. *J Autism Dev Disord.* 2011;41(11):1515-1522.
37. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. *Neuron.* 2012;74(2):285-299.

Bacterial Infections of the Central Nervous System

Katharina M. Busl, MD, MS; Thomas P. Bleck, MD

References

Articles of particular interest, published recently, are indicated as follows: •, of importance; ••, of major importance. Annotations are provided for these articles.

1. Kramer AH, Bleck TP. Neurocritical care of patients with central nervous system infections. *Curr Infect Dis Rep.* 2007;9(4):308-314.
2. Diringer MN, Reaven NL, Funk SE, Uman GC. Elevated body temperature independently contributes to increased length of stay in neurologic intensive care unit patients. *Crit Care Med.* 2004;32(7):1489-1495.
3. Tunkel AR, Scheld WM. Acute meningitis. In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases.* Philadelphia, PA: Elsevier; 2005:1083-1126.
4. Diringer MN, Zazulia AR. Osmotic therapy: fact and fiction. *Neurocrit Care.* 2004;1(2):219-233.
5. Angswurm K, Reuss S, Freyer D, et al. Induced hypothermia in experimental pneumococcal meningitis. *J Cereb Blood Flow Metab.* 2000;20(5):834-838.
6. Cuthbertson BH, Dickson R, Mackenzie A. Intracranial pressure measurement, induced hypothermia and barbiturate coma in meningitis associated with intractable raised intracranial pressure. *Anaesthesia.* 2004;59(9):908-911.
7. Schwab S, Junger E, Spranger M, et al. Craniectomy: an aggressive treatment approach in severe encephalitis. *Neurology.* 1997;48(2):412-417.
8. Claassen J, Mayer SA, Kowalski RG, et al. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. *Neurology.* 2004;62(10):1743-1748.
9. Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. *Pediatr Infect Dis J.* 1993;12(5):389-394.
10. Grimwood K, Anderson P, Anderson V, et al. Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. *Arch Dis Child.* 2000;83(2):111-116.
11. Short WR, Tunkel AR. Changing epidemiology of bacterial meningitis in the United States. *Curr Infect Dis Rep.* 2000;2(4):327-331.
12. van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. *N Engl J Med.* 2006;354(1):44-53.
13. van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. *N Engl J Med.* 2004;351(18):1849-1859.
14. •• Thigpen MC, Whitney CG, Messonnier NE, et al. Bacterial meningitis in the United States, 1998-2007. *N Engl J Med.* 2011;364(21):2016-2025. This article provides an updated overview of the epidemiology and pathogens of bacterial meningitis in the United States over the past decade.
15. Quagliarello V, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. *N Engl J Med.* 1992;327(12):864-872.
16. Tunkel AR. *Bacterial Meningitis.* Philadelphia, PA: Lippincott Williams & Wilkins; 2001.
17. Grandgirard D, Leib SL. Strategies to prevent neuronal damage in paediatric bacterial meningitis. *Curr Opin Pediatr.* 2006;18(2):112-118.
18. Curtis S, Stobart K, Vandermeer B, et al. Clinical features suggestive of meningitis in children: a systematic review of prospective data. *Pediatrics.* 2010;126(5):952-960.
19. Flores-Cordero JM, Amaya-Villar R, Rincón-Ferrari MD, et al. Acute community-acquired bacterial meningitis in adults admitted to the intensive care unit: clinical manifestations, management and prognostic factors. *Intensive Care Med.* 2003;29(11):1967-1973.
20. Wang KW, Chang WN, Chang HW, et al. The significance of seizures and other predictive factors during the acute illness for the long-term outcome after bacterial meningitis. *Seizure.* 2005;14(8):586-592.
21. Wang KW, Chang WN, Chang HW, et al. Clinical relevance of hydrocephalus in bacterial meningitis in adults. *Surg Neurol.* 2005;64(1):61-65, discussion 66.

22. Weisfelt M, van de Beek D, Spanjaard L, et al. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. *Lancet Neurol.* 2006;5(2):123-129.
23. • Jim KK, Brouwer MC, van der Ende A, van de Beek D. Cerebral abscesses in patients with bacterial meningitis. *J Infect.* 2012;64(2):236-238. This article provides the most recent comprehensive analysis of features and occurrence of brain abscess in the setting of bacterial meningitis.
24. Bhimraj A. Acute community-acquired bacterial meningitis in adults: an evidence-based review. *Cleve Clin J Med.* 2012;79(6):393-400.
25. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. *Clin Microbiol Rev.* 2010;23(3):467-492.
26. Michael B, Menezes BF, Cunniffe J, et al. Effect of delayed lumbar punctures on the diagnosis of acute bacterial meningitis in adults. *Emerg Med J.* 2010;27(6):433-438.
27. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults: a review of 493 episodes. *N Engl J Med.* 1993;328(1):21-28.
28. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis.* 2004;39(9):1267-1284.
29. Huy NT, Thao NT, Diep DT, et al. Cerebrospinal fluid lactate concentration to distinguish bacterial from aseptic meningitis: a systemic review and meta-analysis. *Crit Care.* 2010;14(6):R240.
30. • Sakushima K, Hayashino Y, Kawaguchi T, et al. Diagnostic accuracy of cerebrospinal fluid lactate for differentiating bacterial meningitis from aseptic meningitis: a meta-analysis. *J Infect.* 2011;62(4):255-262. This article offers a comprehensive analysis and review of data available regarding laboratory distinction of different forms of meningitis by testing CSF lactate.
31. Brouwer MC, Thwaites GE, Tunkel AR, van de Beek D. Dilemmas in the diagnosis of acute community-acquired bacterial meningitis. *Lancet.* 2012;380(9854):1684-1692.
32. Linder A, Akesson P, Brink M, et al. Heparin-binding protein: a diagnostic marker of acute bacterial meningitis. *Crit Care Med.* 2011;39(4):812-817.
33. Stahel PF, Nadal D, Pfister HW, et al. Complement C3 and factor B cerebrospinal fluid concentrations in bacterial and aseptic meningitis. *Lancet.* 1997;349(9069):1886-1887.
34. Dubos F, Korczowski B, Aygun DA, et al. Serum procalcitonin level and other biological markers to distinguish between bacterial and aseptic meningitis in children: a European multicenter case cohort study. *Arch Pediatr Adolesc Med.* 2008;162(12):1157-1163.
35. Proulx N, Frechette D, Toye B, et al. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. *QJM.* 2005;98(4):291-298.
36. Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. *Crit Care Med.* 2006;34(11):2758-2765.
37. de Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. *N Engl J Med.* 2002;347(20):1549-1556.
38. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. *Lancet Neurol.* 2010;9(3):254-263.
39. Assiri AM, Alasmari FA, Zimmerman VA, et al. Corticosteroid administration and outcome of adolescents and adults with acute bacterial meningitis: a meta-analysis. *Mayo Clin Proc.* 2009;84(5):403-409.
40. Vardakas KZ, Matthaiou DK, Falagas ME. Adjunctive dexamethasone therapy for bacterial meningitis in adults: a meta-analysis of randomized controlled trials. *Eur J Neurol.* 2009;16(6):662-673.
41. Lindvall P, Ahlm C, Ericsson M, et al. Reducing intracranial pressure may increase survival among patients with bacterial meningitis. *Clin Infect Dis.* 2004;38(3):384-390.
42. McIntyre PB, O'Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. *Lancet.* 2012;380(9854):1703-1711.
43. Baltas I, Tsoulfa S, Sakellariou P, et al. Posttraumatic meningitis: bacteriology, hydrocephalus, and outcome. *Neurosurgery.* 1994;35(3):422-426, discussion 426-427.
44. Bullock MR, Chesnut R, Ghajar J, et al. Surgical management of depressed cranial fractures. *Neurosurgery.* 2006;58(3)(suppl):S56-S60, discussion Si-Siv.
45. Tunkel AR, Turtz AR. Post-traumatic infections of the central nervous system. In: Evans RW, ed. *Neurology and Trauma.* New York, NY: Oxford University Press; 2006:628-638.
46. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. *N Engl J Med.* 2010;362(2):146-154.
47. Ratilal B, Costa J, Sampaio C, Pappamikail L. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. *Cochrane Database Syst Rev.* 2011;(8):CD004884. doi:10.1002/14651858.CD004884.pub3.
48. Mathisen GE, Johnson JP. Brain abscess. *Clin Infect Dis.* 1997;25(4):763-779, quiz 780-781.
49. Nathoo N, Nadvi SS, Narotam PK, van Dellen JR. Brain abscess: management and outcome analysis of a computed tomography era experience with 973 patients. *World Neurosurg.* 2011;75(5-6):716-726, discussion 612-617.
50. Tsou TP, Lee PI, Lu CY, et al. Microbiology and epidemiology of brain abscess and subdural empyema in a medical center: a 10-year experience. *J Microbiol Immunol Infect.* 2009;42(5):405-412.

51. Gadgil N, Chamoun RB, Gopinath SP. Intraventricular brain abscess. *J Clin Neurosci*. 2012;19(9):1314-1316.
52. Lambo A, Nchimi A, Khamis J, et al. Primary intraventricular brain abscess. *Neuroradiology*. 2003;45(12):908-910.
53. Manzar N, Manzar B, Kumar R, Bari ME. The study of etiologic and demographic characteristics of intracranial brain abscess: a consecutive case series study from Pakistan. *World Neurosurg*. 2011;76(1-2):195-200, discussion 79-83.
54. Carpenter J, Stapleton S, Holliman R. Retrospective analysis of 49 cases of brain abscess and review of the literature. *Eur J Clin Microbiol Infect Dis*. 2007;26(1):1-11.
55. Xiao F, Tseng MY, Teng LJ, et al. Brain abscess: clinical experience and analysis of prognostic factors. *Surg Neurol*. 2005;63(5):442-449, discussion 449-450.
56. Mampalam TJ, Rosenblum ML. Trends in the management of bacterial brain abscesses: a review of 102 cases over 17 years. *Neurosurgery*. 1988;23(4):451-458.
57. • Arlotti M, Grossi P, Pea F, et al. Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. *Int J Infect Dis*. 2010;14(suppl 4):S79-S92. This article provides a consensus guideline approach to the topic of treatment of brain abscess.
58. Bayston R, de Louvois J, Brown EM, et al. Use of antibiotics in penetrating craniocerebral injuries: "Infection in Neurosurgery" Working Party of British Society for Antimicrobial Chemotherapy. *Lancet*. 2000;355(9217):1813-1817.
59. Lee TH, Chang WN, Su TM, et al. Clinical features and predictive factors of intraventricular rupture in patients who have bacterial brain abscesses. *J Neurol Neurosurg Psychiatry*. 2007;78(3):303-309.
60. Kourbeti IS, Jacobs AV, Koslow M, et al. Risk factors associated with postcraniotomy meningitis. *Neurosurgery*. 2007;60(2):317-325, discussion 325-326.
61. McClelland S III, Hall WA. Postoperative central nervous system infection: incidence and associated factors in 2111 neurosurgical procedures. *Clin Infect Dis*. 2007;45(1):55-59.
62. Korinek AM, Bagnon T, Golmard JL, et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. *Neurosurgery*. 2006;59(1):126-133, discussion 126-133.
63. Leib SL, Boscacci R, Gratzl O, Zimmerli W. Predictive value of cerebrospinal fluid (CSF) lactate level versus CSF/blood glucose ratio for the diagnosis of bacterial meningitis following neurosurgery. *Clin Infect Dis*. 1999;29(1):69-74.
64. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis*. 2011;52(3):e18-e55.
65. Lozier AP, Sciacca RR, Romagnoli MF, et al. Ventriculostomy-related infections: a critical review of the literature. *Neurosurgery*. 2008;62(suppl 2):688-700.
66. Lozier AP, Sciacca RR, Romagnoli MF, Connolly Jr ES. Ventriculostomy-related infections: a critical review of the literature. *Neurosurgery*. 2002;51(1):170-181, discussion 181-182.
67. Lyke KE, Obasanjo OO, Williams MA, et al. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients. *Clin Infect Dis*. 2001;33(12):2028-2033.
68. Mayhall CG, Archer NH, Lamb VA, et al. Ventriculostomy-related infections: a prospective epidemiologic study. *N Engl J Med*. 1984;310(9):553-559.
69. Hoefnagel D, Dammers R, Ter Laak-Poort MP, et al. Risk factors for infections related to external ventricular drainage. *Acta Neurochir (Wien)*. 2008;150(3):209-214, discussion 214.
70. Chi H, Chang KY, Chang HC, et al. Infections associated with indwelling ventriculostomy catheters in a teaching hospital. *Int J Infect Dis*. 2010;14(3):e216-e219.
71. Tse T, Cheng K, Wong K, et al. Ventriculostomy and infection: a 4-year-review in a local hospital. *Surg Neurol Int*. 2010;1:47.
72. Holloway KL, Barnes T, Choi S, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. *J Neurosurg*. 1996;85(3):419-424.
73. Arabi Y, Memish ZA, Balkhy HH, et al. Ventriculostomy-associated infections: incidence and risk factors. *Am J Infect Control*. 2005;33(3):137-143.
74. Stenehjelm E, Armstrong WS. Central nervous system device infections. *Infect Dis Clin North Am*. 2012;26(1):89-110.
75. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control*. 2008;36(5):309-332.
76. Ross D, Rosegay H, Pons V. Differentiation of aseptic and bacterial meningitis in postoperative neurosurgical patients. *J Neurosurg*. 1988;69(5):669-674.
77. Schade RP, Schinkel J, Roelandse FW, et al. Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis. *J Neurosurg*. 2006;104(1):101-108.
78. Pfausler B, Beer R, Engelhardt K, et al. Cell index—a new parameter for the early diagnosis of ventriculostomy (external ventricular drainage)-related ventriculitis in patients with intraventricular hemorrhage? *Acta Neurochir (Wien)*. 2004;146(5):477-481.
79. Wong GK, Poon WS, Ip M. Use of ventricular cerebrospinal fluid lactate measurement to diagnose cerebrospinal fluid infection in patients with intraventricular haemorrhage. *J Clin Neurosci*. 2008;15(6):654-655.
80. Sundbarg G, Nordstrom CH, Söderström S. Complications due to prolonged ventricular fluid pressure recording. *Br J Neurosurg*. 1988;2(4):485-495.
81. Camacho EF, Boszczowski I, Basso M, et al. Infection rate and risk factors associated with infections related to external ventricular drain. *Infection*. 2011;39(1):47-51.

82. Scheithauer S, Burgel U, Bickenbach J, et al. External ventricular and lumbar drainage-associated meningoventriculitis: prospective analysis of time-dependent infection rates and risk factor analysis. *Infection*. 2010;38(3):205-209.
83. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. *Ann Pharmacother*. 2007;41(2):296-308.
84. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. *Expert Opin Drug Metab Toxicol*. 2007;3(4):573-581.
85. Tangden T, Enblad P, Ullberg M, Sjölin J. Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases. *Clin Infect Dis*. 2011;52(11):1310-1316.
86. Elvy J, Porter D, Brown E. Treatment of external ventricular drain-associated ventriculitis caused by *Enterococcus faecalis* with intraventricular daptomycin. *J Antimicrob Chemother*. 2008;61(2):461-462.
87. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant *Acinetobacter* species. *Lancet Infect Dis*. 2009;9(4):245-255.
88. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;49(1):1-45.
89. Korinek AM, Fulla-Oller L, Boch AL, et al. Morbidity of ventricular cerebrospinal fluid shunt surgery in adults: an 8-year study. *Neurosurgery*. 2011;68(4):985-994, discussion 994-995.
90. Conen A, Walti LN, Merlo A, et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. *Clin Infect Dis*. 2008;47(1):73-82.
91. Laxmi S, Tunkel AR. Healthcare-associated bacterial meningitis. *Curr Infect Dis Rep*. 2011;13(4):367-373.
92. Whitehead WE, Kestle JR. The treatment of cerebrospinal fluid shunt infections: results from a practice survey of the American Society of Pediatric Neurosurgeons. *Pediatr Neurosurg*. 2001;35(4):205-210.
93. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. *N Engl J Med*. 2006;355(26):2725-2732.
94. •• Leverstein-van Hall MA, Hopmans TE, van der Sprenkel JW, et al. A bundle approach to reduce the incidence of external ventricular and lumbar drain-related infections. *J Neurosurg*. 2010;112(2):345-353. This article features the changes in occurrence of EVD-related infections with introduction of infection control by using a bundle approach.
95. Korinek AM, Reina M, Boch AL, et al. Prevention of external ventricular drain-related ventriculitis. *Acta Neurochir (Wien)*. 2005;147(1):39-45, discussion 45-46.
96. Alleyne CH Jr, Hassan M, Zabramski JM. The efficacy and cost of prophylactic and perioperative antibiotics in patients with external ventricular drains. *Neurosurgery*. 2000;47(5):1124-1127, discussion 1127-1129.
97. Poon WS, Ng S, Wai S. CSF antibiotic prophylaxis for neurosurgical patients with ventriculostomy: a randomised study. *Acta Neurochir Suppl*. 1998;71:146-148.
98. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. *Cochrane Database Syst Rev*. 2006;(3):CD005365. doi:10.1002/14651858.CD005365.pub2.
99. Zabramski JM, Whiting D, Darouiche RO, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. *J Neurosurg*. 2003;98(4):725-730.
100. Abila AA, Zabramski JM, Jahnke HK, et al. Comparison of two antibiotic-impregnated ventricular catheters: a prospective sequential series trial. *Neurosurgery*. 2011;68(2):437-442, discussion 442.
101. Harrop JS, Sharan AD, Ratliff J, et al. Impact of a standardized protocol and antibiotic-impregnated catheters on ventriculostomy infection rates in cerebrovascular patients. *Neurosurgery*. 2010;67(1):187-191, discussion 191.
102. Stevens EA, Palavecino E, Sherertz RJ, et al. Effects of antibiotic-impregnated external ventricular drains on bacterial culture results: an in vitro analysis. *J Neurosurg*. 2010;113(1):86-92.
103. Fichtner J, Guresir E, Seifert V, Raabe A. Efficacy of silver-bearing external ventricular drainage catheters: a retrospective analysis. *J Neurosurg*. 2010;112(4):840-846.
104. Baer ET. Post-dural puncture bacterial meningitis. *Anesthesiology*. 2006;105(2):381-393.
105. Governale LS, Fein N, Logsdon J, Black PM. Techniques and complications of external lumbar drainage for normal pressure hydrocephalus. *Neurosurgery*. 2008;63(4)(suppl 2):379-384, discussion 384.
106. Piek J, Bock WJ. Continuous monitoring of cerebral tissue pressure in neurosurgical practice—experiences with 100 patients. *Intensive Care Med*. 1990;16(3):184-188.
107. Gelabert-Gonzalez M, Ginesta-Galan V, Sernamito-García R, et al. The Camino intracranial pressure device in clinical practice: assessment in a 1000 cases. *Acta Neurochir (Wien)*. 2006;148(4):435-441.
108. Martinez-Manas RM, Santamarta D, de Campos JM, Ferrer E. Camino intracranial pressure monitor: prospective study of accuracy and complications. *J Neurol Neurosurg Psychiatry*. 2000;69(1):82-86.
109. May AK, Fleming SB, Carpenter RO, et al. Influence of broad-spectrum antibiotic prophylaxis on intracranial pressure monitor infections and subsequent infectious complications in head-injured patients. *Surg Infect (Larchmt)*. 2006;7(5):409-417.
110. Poca MA, Sahuquillo J, Arribas M, et al. Fiberoptic intraparenchymal brain pressure monitoring with the Camino V420 monitor: reflections on our experience in 163 severely head-injured patients. *J Neurotrauma*. 2002;19(4):439-448.

111. Shapiro S, Bowman R, Callahan J, Wolfla C. The fiberoptic intraparenchymal cerebral pressure monitor in 244 patients. *Surg Neurol.* 1996;45(3):278-282.
112. Stoikes NF, Magnotti LJ, Hodges TM, et al. Impact of intracranial pressure monitor prophylaxis on central nervous system infections and bacterial multi-drug resistance. *Surg Infect (Larchmt).* 2008;9(5):503-508.
113. Morton R, Lucas TH II, Ko A, et al. Intracerebral abscess associated with the Camino intracranial pressure monitor: case report and review of the literature. *Neurosurgery.* 2012;71(1):E193-E198.
114. Fily F, Haegelen C, Tattevin P, et al. Deep brain stimulation hardware-related infections: a report of 12 cases and review of the literature. *Clin Infect Dis.* 2011;52(8):1020-1023.
115. Vergani F, Landi A, Pirillo D, et al. Surgical, medical, and hardware adverse events in a series of 141 patients undergoing subthalamic deep brain stimulation for Parkinson disease. *World Neurosurg.* 2010;73(4):338-344.
116. Gorgulho A, Juillard C, Uslan DZ, et al. Infection following deep brain stimulator implantation performed in the conventional versus magnetic resonance imaging-equipped operating room. *J Neurosurg.* 2009;110(2):239-246.
117. Anderson DJ, Kaye KS, Classen D, et al. Strategies to prevent surgical site infections in acute care hospitals. *Infect Control Hosp Epidemiol.* 2008;29(suppl 1):S51-S61.
118. Zuger A. Tuberculosis. In: Scheld WM, Whitley RJ, Marra CM, eds. *Infections of the Central Nervous System.* Philadelphia, PA: Lippincott Williams & Wilkins; 2004:441-460.
119. Chatterjee S. Brain tuberculomas, tubercular meningitis, and posttubercular hydrocephalus in children. *J Pediatr Neurosci.* 2011;6(suppl 1):S96-S100.
120. Pehlivanoglu F, Yasar KK, Sengoz G. Tuberculous meningitis in adults: a review of 160 cases. *ScientificWorldJournal.* 2012;2012:169028.
121. Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis. *Eur J Neurol.* 2007;14(1):33-37.
122. Sinner SW. Approach to the diagnosis and management of tuberculous meningitis. *Curr Infect Dis Rep.* 2010;12(4):291-298.
123. Moghtaderi A, Alavi-Naini R, Izadi S, Cuevas LE. Diagnostic risk factors to differentiate tuberculous and acute bacterial meningitis. *Scand J Infect Dis.* 2009;41(3):188-194.
124. Katrak SM, Shembalkar PK, Bijwe SR, Bhandarkar LD. The clinical, radiological and pathological profile of tuberculous meningitis in patients with and without human immunodeficiency virus infection. *J Neurol Sci.* 2000;181(1-2):118-126.
125. Lammie GA, Hewlett RH, Schoeman JF, Donald PR. Tuberculous cerebrovascular disease: a review. *J Infect.* 2009;59(3):156-166.
126. Kalita J, Misra UK, Nair PP. Predictors of stroke and its significance in the outcome of tuberculous meningitis. *J Stroke Cerebrovasc Dis.* 2009;18(4):251-258.
127. Thwaites GE, Chau TT, Stepniewska K, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. *Lancet.* 2002;360(9342):1287-1292.
128. Katti MK. Pathogenesis, diagnosis, treatment, and outcome aspects of cerebral tuberculosis. *Med Sci Monit.* 2004;10(9):RA215-RA229.
129. Rafi W, Venkataswamy MM, Nagarathna S, et al. Role of IS6110 uniplex PCR in the diagnosis of tuberculous meningitis: experience at a tertiary neurocentre. *Int J Tuberc Lung Dis.* 2007;11(2):209-214.
130. Pai M, Flores LL, Pai N, et al. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2003;3(10):633-643.
131. Wasay M, Kheleani BA, Moolani MK, et al. Brain CT and MRI findings in 100 consecutive patients with intracranial tuberculoma. *J Neuroimaging.* 2003;13(3):240-247.
132. Thwaites GE, Tran TH. Tuberculous meningitis: many questions, too few answers. *Lancet Neurol.* 2005;4(3):160-170.
133. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. *MMWR Recomm Rep.* 2003;52(RR-11):1-77.
134. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. *Am J Respir Crit Care Med.* 2003;167(4):603-662.
135. Takahashi T, Ogawa K, Sawada S, et al. A case of refractory tuberculous meningitis markedly improved by intrathecal administration of isoniazid (INH). *Rinsho Shinkeigaku.* 2003;43(1-2):20-25.
136. Prasad K, Singh MB. Corticosteroids for managing tuberculous meningitis. *Cochrane Database Syst Rev.* 2008;(1):CD002244. doi:10.1002/14651858.CD002244.pub3.
137. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. *Clin Infect Dis.* 2011;52(11):1374-1383.
138. Brancusi F, Farrar J, Heemskerk D. Tuberculous meningitis in adults: a review of a decade of developments focusing on prognostic factors for outcome. *Future Microbiol.* 2012;7(9):1101-1116.
139. Tan EK, Chee MW, Chan LL, Lee YL. Culture positive tuberculous meningitis: clinical indicators of poor prognosis. *Clin Neurol Neurosurg.* 1999;101(3):157-160.
140. Rajshekhar V. Management of hydrocephalus in patients with tuberculous meningitis. *Neurol India.* 2009;57(4):368-374.
141. Török ME, Nguyen DB, Tran TH, et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. *PLoS One.* 2011;6(12):e27821.
142. Mamelak AN, Obana WG, Flaherty JF, Rosenblum ML. Nocardial brain abscess: treatment strategies and factors influencing outcome. *Neurosurgery.* 1994;35(4):622-631.

143. Lee GY, Daniel RT, Brophy BP, Reilly PL. Surgical treatment of nocardial brain abscesses. *Neurosurgery*. 2002;51(3):668-671, discussion 671-672.
144. Beaman BL, Beaman L. Nocardia species: host-parasite relationships. *Clin Microbiol Rev*. 1994;7(2):213-264.
145. Barnicoat MJ, Wierzbicki AS, Norman PM. Cerebral nocardiosis in immunosuppressed patients: five cases. *Q J Med*. 1989;72(268):689-698.
146. Uttamchandani RB, Daikos GL, Reyes RR, et al. Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome. *Clin Infect Dis*. 1994;18(3):348-353.
147. Lerner PI. Nocardiosis. *Clin Infect Dis*. 1996;22(6):891-903, quiz 904-905.
148. Torres OH, Domingo P, Pericas R, et al. Infection caused by *Nocardia farcinica*: case report and review. *Eur J Clin Microbiol Infect Dis*. 2000;19(3):205-212.
149. Cianfoni A, Calandrelli R, De Bonis P, et al. Nocardia brain abscess mimicking high-grade necrotic tumor on perfusion MRI. *J Clin Neurosci*. 2010;17(8):1080-1082.
150. Hall WA, Martinez AJ, Dummer JS, Lunsford LD. Nocardial brain abscess: diagnostic and therapeutic use of stereotactic aspiration. *Surg Neurol*. 1987;28(2):114-118.
151. Wallace RJ Jr, Steele LC, Sumter G, Smith JM. Antimicrobial susceptibility patterns of *Nocardia asteroides*. *Antimicrob Agents Chemother*. 1988;32(12):1776-1779.
152. Kilincer C, Hamamcioglu MK, Simsek O, et al. Nocardial brain abscess: review of clinical management. *J Clin Neurosci*. 2006;13(4):481-485.
153. Geiseler PJ, Andersen BR. Results of therapy in systemic nocardiosis. *Am J Med Sci*. 1979;278(3):188-194.
154. Smego RA Jr, Moeller MB, Gallis HA. Trimethoprim-sulfamethoxazole therapy for *Nocardia* infections. *Arch Intern Med*. 1983;143(4):711-718.
155. Obana WG, Rosenblum ML. Surgery for intracranial infections. In: Post KD, Friedman ED, McCormick P, eds. *Postoperative Complications in Intracranial Neurosurgery*. New York, NY: Thieme; 1993:146-156.
156. US Department of Health and Human Services. *Sexually Transmitted Disease Surveillance*. Atlanta, GA: Centers for Disease Control and Prevention; 2008:2009.
157. Ciesielski CA. Sexually transmitted diseases in men who have sex with men: an epidemiologic review. *Curr Infect Dis Rep*. 2003;5(2):145-152.
158. Hook EW III, Marra CM. Acquired syphilis in adults. *N Engl J Med*. 1992;326(16):1060-1069.
159. Tramont EC. *Treponema pallidum* (Syphilis). In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases*. Orlando, FL: Churchill Livingstone; 2005:2768-2784.
160. Simon RP. Neurosyphilis. *Arch Neurol*. 1985;42(6):606-613.
161. Kent ME, Romanelli F. Reexamining syphilis: an update on epidemiology, clinical manifestations, and management. *Ann Pharmacother*. 2008;42(2):226-236.
162. Ghanem KG. Review: neurosyphilis: a historical perspective and review. *CNS Neurosci Ther*. 2010;16(5):e157-e168.
163. Asdaghi N, Muayqil T, Scozzafava J, et al. The re-emergence in Canada of meningovascular syphilis: 2 patients with headache and stroke. *CMAJ*. 2007;176(12):1699-1700.
164. Merritt HH. The early clinical and laboratory manifestations of syphilis of the central nervous system. *New Engl J Med*. 1940;223:446-450.
165. Gurses C, Bilgic B, Topçular B, et al. Clinical and magnetic resonance imaging findings of HIV-negative patients with neurosyphilis. *J Neurol*. 2007;254(3):368-374.
166. Harris DE, Enterline DS, Tien RD. Neurosyphilis in patients with AIDS. *Neuroimaging Clin N Am*. 1997;7(2):215-221.
167. • Chahine LM, Khoriaty RN, Tomford WJ, Hussain MS. The changing face of neurosyphilis. *Int J Stroke*. 2011;6(2):136-143. In this article, an updated view on neurosyphilis in the era of AIDS and HIV is provided, outlining the outdated prior presentations and featuring the new presentations of neurosyphilis.
168. Gaa J, Weidauer S, Sitzer M, et al. Cerebral vasculitis due to *Treponema pallidum* infection: MRI and MRA findings. *Eur Radiol*. 2004;14(4):746-747.
169. Flint AC, Liberato BB, Anziska Y, et al. Meningovascular syphilis as a cause of basilar artery stenosis. *Neurology*. 2005;64(2):391-392.
170. Vatz KA, Scheibel RL, Keiffer SA, Ansari KA. Neurosyphilis and diffuse cerebral angiopathy: a case report. *Neurology*. 1974;24(5):472-476.
171. Holmes MD, Brant-Zawadzki MM, Simon RP. Clinical features of meningovascular syphilis. *Neurology*. 1984;34(4):553-556.
172. Szilak I, Marty F, Helft J, Soeiro R. Neurosyphilis presenting as herpes simplex encephalitis. *Clin Infect Dis*. 2001;32(7):1108-1109.
173. Romberg EH. Pupillary disturbances in tabes. *Z Gesamte Neurol Psy*. 1939;165:369-372.
174. Musher DM, Hamill RJ, Baughn RE. Effect of human immunodeficiency virus (HIV) infection on the course of syphilis and on the response to treatment. *Ann Intern Med*. 1990;113(11):872-881.
175. Ghanem KG, Moore RD, Rompalo AM, et al. Neurosyphilis in a clinical cohort of HIV-1-infected patients. *AIDS*. 2008;22(10):1145-1151.
176. Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. *J Infect Dis*. 2004;189(3):369-376.
177. Walter T, Lebouche B, Miaillhes P, et al. Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. *Clin Infect Dis*. 2006;43(6):787-790.
178. Bordón J, Martínez-Vázquez C, Álvarez M, et al. Neurosyphilis in HIV-infected patients. *Eur J Clin Microbiol Infect Dis*. 1995;14(10):864-869.

179. Berger JR. Neurosyphilis in human immunodeficiency virus type 1-seropositive individuals: a prospective study. *Arch Neurol.* 1991;48(7):700-702.
180. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines. *MMWR Recomm Rep.* 2006;55(RR-11):1-94.
181. Centers for Disease Control and Prevention (CDC). Symptomatic early neurosyphilis among HIV-positive men who have sex with men—four cities, United States, January 2002–June 2004. *MMWR Morb Mortal Wkly Rep.* 2007;56(25):625-628.
182. Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. *JAMA.* 2003;290(11):1510-1514.
183. Smith G, Holman RP. The prozone phenomenon with syphilis and HIV-1 co-infection. *South Med J.* 2004;97(4):379-382.
184. Davis LE, Schmitt JW. Clinical significance of cerebrospinal fluid tests for neurosyphilis. *Ann Neurol.* 1989;25(1):50-55.
185. Marshall DW, Brey RL, Cahill WT, et al. Spectrum of cerebrospinal fluid findings in various stages of human immunodeficiency virus infection. *Arch Neurol.* 1988;45(9):954-958.
186. Marra CM, Maxwell CL, Collier AC, et al. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. *BMC Infect Dis.* 2007;7:37.
187. Bartt R. Listeria and atypical presentations of Listeria in the central nervous system. *Semin Neurol.* 2000;20(3):361-373.
188. Southwick FS, Purich DL. Intracellular pathogenesis of listeriosis. *N Engl J Med.* 1996;334(12):770-776.
189. Embil JA, Ewan EP, MacDonald SW. Surveillance of *Listeria monocytogenes* in human and environmental specimens in Nova Scotia, 1974 to 1981. *Clin Invest Med.* 1984;7(4):325-327.
190. Armstrong D. Listeria monocytogenes. In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and Practice of Infectious Diseases.* New York, NY: Churchill Livingstone; 1995:1880-1885.
191. Disson O, Lecuit M. Targeting of the central nervous system by *Listeria monocytogenes*. *Virulence.* 2012;3(2):213-221.
192. McLauchlin J. Human listeriosis in Britain, 1967-85, a summary of 722 cases: 2. listeriosis in non-pregnant individuals, a changing pattern of infection and seasonal incidence. *Epidemiol Infect.* 1990;104(2):191-201.
193. Mylonakis E, Hohmann EL, Calderwood SB. Central nervous system infection with *Listeria monocytogenes*: 33 years' experience at a general hospital and review of 776 episodes from the literature. *Medicine (Baltimore).* 1998;77(5):313-336.
194. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995: Active Surveillance Team. *N Engl J Med.* 1997;337(14):970-976.
195. Skogberg K, Syrjanen J, Jahkola M, et al. Clinical presentation and outcome of listeriosis in patients with and without immunosuppressive therapy. *Clin Infect Dis.* 1992;14(4):815-821.
196. Watson GW, Fuller TJ, Elms J, Kluge RM. Listeria cerebritis: relapse of infection in renal transplant patients. *Arch Intern Med.* 1978;138(1):83-87.
197. Grotta J, Nelson W, Matocha J. Listeria encephalitis. *Arch Neurol.* 1981;38(3):200.
198. Harris JO, Marquez J, Swerdloff MA, Magana IA. Listeria brain abscess in the acquired immunodeficiency syndrome. *Arch Neurol.* 1989;46(3):250.
199. Dee RR, Lorber B. Brain abscess due to *Listeria monocytogenes*: case report and literature review. *Rev Infect Dis.* 1986;8(6):968-77.
200. Chu JY, Montanera W, Willinsky RA. Listeria spinal cord abscess—clinical and MRI findings. *Can J Neurol Sci.* 1996;23(3):220-223.
201. Armstrong RW, Fung PC. Brainstem encephalitis (rhombencephalitis) due to *Listeria monocytogenes*: case report and review. *Clin Infect Dis.* 1993;16(5):689-702.
202. Heck EF. *Listeria monocytogenes*. In: Vinken PJ, Bruyn GW, Klawans HL, eds. *Handbook of Clinical Neurology.* Amsterdam, Netherlands: Elsevier Scientific; 1978:77-95.
203. Uldry PA, Kuntzer T, Bogousslavsky J, et al. Early symptoms and outcome of *Listeria monocytogenes* rhombencephalitis: 14 adult cases. *J Neurol.* 1993;240(4):235-242.
204. Salgado MJ, Damani NN, Llewellyn CG, et al. Magnetic resonance imaging of abscesses of the brain stem and cerebellum complicating *Listeria monocytogenes* rhombencephalitis. *Can Assoc Radiol J.* 1996;47(6):431-433.
205. Lavetter A, Leedom JM, Mathies AW Jr, Ivler D, Wehrle PF. Meningitis due to *Listeria monocytogenes*: a review of 25 cases. *N Engl J Med.* 1971;285(11):598-603.
206. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. *N Engl J Med.* 1997;336(10):708-716.
207. Rapp MF, Pershadsingh HA, Long JW Jr, Pickens JM. Ampicillin-resistant *Listeria monocytogenes* meningitis in a previously healthy 14-year-old athlete. *Arch Neurol.* 1984;41(12):1304.
208. Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. *Ann Intern Med.* 1984;100(6):881-890.

Chronic Epilepsy Due to Low Grade Temporal Lobe Tumors and Due to Hippocampal Sclerosis: Do They Differ in Postsurgical Outcome?

Prasad S. S. V. Vannemreddy, MD; Andres M. Kanner, MD; Michael C. Smith, MD; Marvin Rossi, MD, PhD; David Wallace, MD; Siddharth N. K. Vannemreddy, MD; Richard W. Byrne, MD

References

1. Hughlings Jackson J. A case of convulsive seizures beginning in the right foot owing to cortical tumour of the left cerebral hemisphere. *Proc Med Soc London*. 1882;6:151-152.
2. Berger MS, Ghatan S, Haglund MM, Dobbins J, Ojemann GA. Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. *J Neurosurg*. 1993;79(1):62-69.
3. Kirkpatrick PJ, Honavar M, Janota I, Polkey CE. Control of temporal lobe epilepsy following en bloc resection of low-grade tumors. *J Neurosurg*. 1993;78(1):19-25.
4. Khajavi K, Comair YG, Wyllie E, Palmer J, Morris HH, Hahn FJ. Surgical management of pediatric tumor-associated epilepsy. *J Child Neurol*. 1999;14(1):15-25.
5. Iannelli A, Guzetta F, Battaglia D, Iuvone L, Di Rocco C. Surgical treatment of temporal tumors associated with epilepsy in children. *Pediatr Neurosurg*. 2000;32(5):248-254.
6. Packer RJ, Sutton LN, Patel KM, et al. Seizure control following tumor surgery for childhood cortical low-grade gliomas. *J Neurosurg*. 1994;80(6):998-1003.
7. Zentner J, Hufnagel A, Wolf HK, et al. Surgical treatment of neoplasms associated with medically intractable epilepsy. *Neurosurgery*. 1997;41(2):378-387.
8. Meyer A, Falconer MA, Beck E. Pathological findings in temporal lobe epilepsy. *J Neurol Neurosurg Psychiatry*. 1954;17(4):276-285.
9. Margerison JH, Corsellis JA. Epilepsy and the temporal lobes: a clinical, electroencephalographic and neuropathological study of the brain in epilepsy, with particular reference to the temporal lobes. *Brain*. 1966;89(3):499-530.
10. Bernasconi A, Bernasconi N, Caramanos Z, et al. T2 relaxometry can lateralize mesial temporal lobe epilepsy in patients with normal MRI. *Neuroimage*. 2000;12(6):739-746.
11. Kuzniecky R, Ho SS, Martin R, et al. Temporal lobe developmental malformations and hippocampal sclerosis: epilepsy surgical outcome. *Neurology*. 1999;52(3):479-484.
12. Raymond AA, Fish DR, Stevens JM, Cook MJ, Sisodiya SM, Shorvon SD. Association of hippocampal sclerosis with cortical dysgenesis in patients with epilepsy. *Neurology*. 1994;44(10):1841-1845.
13. Moran NF, Lemieux L, Kitchen ND, Fish DR, Shorvon SD. Extrahippocampal temporal lobe atrophy in temporal lobe epilepsy and mesial temporal sclerosis. *Brain*. 2001;124(pt 1):167-175.
14. Bernasconi N, Natsume J, Bernasconi A. Progression in temporal lobe epilepsy: differential atrophy in mesial temporal structures. *Neurology*. 2005;65(2):223-228.
15. López HE, Fohlen M, Lelouch-Tubiana A, et al. Heterotopia associated with hippocampal sclerosis: an under-recognized cause of early onset epilepsy in children operated on for temporal lobe epilepsy. *Neuropediatrics*. 2010;41(4):167-175.
16. Benifla M, Otsubo H, Ochi A, et al. Temporal lobe surgery for intractable epilepsy in children: an analysis of outcomes in 126 children. *Neurosurgery*. 2006;59(6):1203-1213.
17. Mittal S, Montes JL, Farmer JP, et al. Long-term outcome after surgical treatment of temporal lobe epilepsy in children. *J Neurosurg*. 2005;103(5)(suppl):401-412.
18. Nolan MA, Sakuta R, Chuang N, et al. Dysembryoplastic neuroepithelial tumors in childhood: long-term outcome and prognostic features. *Neurology*. 2004;62(12):2270-2276.
19. Kwan P, Brodie MJ. Drug treatment of epilepsy: when does it fail and how to optimize its use? *CNS Spectr*. 2004;9(2):110-119.
20. Berg AT, Shinnar S, Levy SR, Testa FM. Newly diagnosed epilepsy in children: presentation at diagnosis. *Epilepsia*. 1999;40(4):445-452.
21. Wolf HK, Campos MG, Zentner J, et al. Surgical pathology of temporal lobe epilepsy: experience with 216 cases. *J Neuropathol Exp Neurol*. 1993;52(5):499-506.
22. Zaatreh MM, Firlik KS, Spencer DD, Spencer SS. Temporal lobe tumoral epilepsy: characteristics and predictors of surgical outcome. *Neurology*. 2003;61(5):636-641.
23. Cataltepe O, Turanli G, Yalnizoglu D, Topçu M, Akalan N. Surgical management of temporal lobe tumor-related epilepsy in children. *J Neurosurg*. 2005;102(3)(suppl):280-287.

24. Phi JH, Kim S, Cho BK, et al. Long-term surgical outcomes of temporal lobe epilepsy associated with low-grade brain tumors. *Cancer*. 2009;115(24):5771-5779.
25. Ruban D, Byrne RW, Kanner AM, et al. Chronic epilepsy associated with temporal tumors: long-term surgical outcome. *Neurosurg Focus*. 2009;27(2):E6.
26. Morris HH, Estes ML, Gilmore R, Van Ness PC, Barnett GH, Turnbull J. Chronic intractable epilepsy as the only symptom of primary brain tumor. *Epilepsia*. 1993;34(6):1038-1043.
27. Tassi L, Meroni A, Deleo F, et al. Temporal lobe epilepsy: neuropathological and clinical correlations in 243 surgically treated patients. *Epileptic Disord*. 2009;11(4):281-292.
28. Blümcke I, Thom M, Wiestler OD. Ammon's horn sclerosis: a maldevelopmental disorder associated with temporal lobe epilepsy. *Brain Pathol*. 2002;12(2):199-211.
29. Britton JW, Cascino GD, Sharbrough FW, Kelly PJ. Low-grade glial neoplasms and intractable partial epilepsy: efficacy of surgical treatment. *Epilepsia*. 1994;35(6):1130-1135.
30. Fried I, Kim JH, Spencer DD. Limbic and neocortical gliomas associated with intractable seizures: a distinct clinicopathological group. *Neurosurgery*. 1994;34(5):815-824.
31. Drake J, Hoffman HJ, Kobayashi J, Hwang P, Becker LE. Surgical management of children with temporal lobe epilepsy and mass lesions. *Neurosurgery*. 1987;21(6):792-797.
32. Jooma R, Yeh HS, Privitera MD, Gartner M. Lesionectomy versus electrophysiologically guided resection for temporal lobe tumors manifesting with complex partial seizures. *J Neurosurg*. 1995;83(2):231-236.
33. Mathern GW, Babb TL, Pretorius JK, Melendez M, Lévesque MF. The pathophysiologic relationships between lesion pathology, intracranial ictal EEG onsets, and hippocampal neuron loss in temporal lobe epilepsy. *Epilepsy Res*. 1995;21(2):133-147.
34. Thom M, Mathern GW, Cross JH, Bertram EH. Mesial temporal lobe epilepsy: how do we improve surgical outcome? *Ann Neurol*. 2010;68(4):424-434.

Detection of Angiographically Occult, Ruptured Cerebral Aneurysms

Michael Chen, MD; Valerie Toll, RN, MSN

References

1. Little AS, Garrett M, Germain R, et al. Evaluation of patients with spontaneous subarachnoid hemorrhage and negative angiography. *Neurosurgery*. 2007;61(6):1139-1150, discussion 50-51.
2. Farres MT, Ferraz-Leite H, Schindler E, Muhlbauer M. Spontaneous subarachnoid hemorrhage with negative angiography: CT findings. *J Comput Assist Tomogr*. 1992;16(4):534-537.
3. Dandy WE. *Intracranial Arterial Aneurysms*. Ithaca, NY; Comstock Publishing Co Inc; 1944.
4. Whittle IR, Dorsch NW, Besser M. Spontaneous thrombosis in giant intracranial aneurysms. *J Neurol Neurosurg Psychiatry*. 1982;45(11):1040-1047.
5. Carlson DH, Thomson D. Spontaneous thrombosis of a giant cerebral aneurysm in five days: report of a case. *Neurology*. 1976;26(4):334-336.
6. Whittle IR, Williams DB, Halmagyi GM, Besser M. Spontaneous thrombosis of a giant intracranial aneurysm and ipsilateral internal carotid artery: case report. *J Neurosurg*. 1982;56(2):287-289.
7. Black SPW, German WJ. Observations on the relationship between the volume and the size of the orifice of experimental aneurysms. *J Neurosurg*. 1960;17:984-990.
8. Gonzalez CF, Cho YI, Ortega HV, Moret J. Intracranial aneurysms: flow analysis of their origin and progression. *AJNR Am J Neuroradiol*. 1992;13(1):181-188.
9. Inamasu J, Nakamura Y, Saito R, et al. "Occult" ruptured cerebral aneurysms revealed by repeat angiography: result from a large retrospective study. *Clin Neurol Neurosurg*. 2003;106(1):33-37.
10. Jafar JJ, Weiner HL. Surgery for angiographically occult cerebral aneurysms. *J Neurosurg*. 1993;79(5):674-679.
11. Hui FK, Schuette AJ, Lieber M, et al. -Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients. *Neurosurgery*. 2012;70(3):702-705, discussion 705-706.
12. Fodstad H, Liliequist B. Spontaneous thrombosis of ruptured intracranial aneurysms during treatment with tranexamic acid (AMCA): report of three cases. *Acta Neurochir (Wien)*. 1979;49(3-4):129-144.
13. Di Lorenzo N, Guidetti G. Anterior communicating aneurysm missed at angiography: report of two cases treated surgically. *Neurosurgery*. 1988;23(4):494-499.
14. Bohmfalk GL, Story JL. Intermittent appearance of a ruptured cerebral aneurysm on sequential angiograms: case report. *J Neurosurg*. 1980;52(2):263-265.
15. Sawiris N, Venizelos A, Ouyang B, Lopes D, Chen M. Current utility of diagnostic catheter cerebral angiography. *J Stroke Cerebrovasc Dis*. 2014;23(3):e145-e150.
16. Nehls DG, Flom RA, Carter LP, Spetzler RF. Multiple intracranial aneurysms: determining the site of rupture. *J Neurosurg*. 1985;63(3):342-348.
17. Marttila I, Heiskanen O. Value of neurological and angiographic signs as indicators of the ruptured aneurysm in patients with multiple intracranial aneurysms. *Acta Neurochir (Wien)*. 1970;23(2):95-102.

Minimally Invasive Thoracic Microendoscopic Discectomy: Surgical Technique and Case Series

Justin S. Smith, MD, PhD; Kurt M. Eichholz, MD;
Stephen Shafizadeh, MD, PhD;
Alfred T. Ogden, MD; John E. O'Toole, MD;
Richard G. Fessler, MD, PhD

References

1. McCormick WE, Will SF, Benzel EC. Surgery for thoracic disc disease: complication avoidance: overview and management. *Neurosurg Focus*. 2000;9(4):13.
2. Faciszewski T, Winter RB, Lonstein JE, Denis F, Johnson L. The surgical and medical perioperative complications of anterior spinal fusion surgery in the thoracic and lumbar spine in adults: a review of 1223 procedures. *Spine (Phila Pa 1976)*. 1995;20(14):1592-1599.
3. Naunheim KS, Barnett MG, Crandall DG, Vaca KJ, Burkus JK. Anterior exposure of the thoracic spine. *Ann Thorac Surg*. 1994;57(6):1436-1439.
4. Sundaresan N, Shah J, Foley KM, Rosen G. An anterior surgical approach to the upper thoracic vertebrae. *J Neurosurg*. 1984;61(4):686-690.
5. Turner PL, Webb JK. A surgical approach to the upper thoracic spine. *J Bone Joint Surg Br*. 1987;69(4):542-544.
6. Bohlman HH, Zdeblick TA. Anterior excision of herniated thoracic discs. *J Bone Joint Surg Am*. 1988;70(7):1038-1047.
7. Fessler RG, Sturgill M. Review: complications of surgery for thoracic disc disease. *Surg Neurol*. 1998;49(6):609-618.
8. Regan JJ, Mack ML, Picetti GDI. A technical report on video-assisted thoracoscopy in thoracic spinal surgery: preliminary description. *Spine*. 1995;20(7):831-837.
9. Anand N, Regan JJ. Video-assisted thoracoscopic surgery for thoracic disc disease: classification and outcome study of 100 consecutive cases with a 2-year minimum follow-up period. *Spine*. 2002;27(8):871-879.
10. Han PP, Kenny K, Dickman CA. Thoracoscopic approaches to the thoracic spine: experience with 241 surgical procedures. *Neurosurgery*. 2002;51(5)(suppl):S88-S95.
11. Dickman CA, Rosenthal D, Karahalios DG, et al. Thoracic vertebrectomy and reconstruction using a microsurgical thoracoscopic approach. *Neurosurgery*. 1996;38(2):279-293.
12. Lidar Z, Lifshutz J, Bhattacharjee S, Kurpad SN, Maiman DJ. Minimally invasive, extracavitary approach for thoracic disc herniation: technical report and preliminary results. *Spine J*. 2006;6(2):157-163.
13. Jho HD. Endoscopic transpedicular thoracic discectomy. *J Neurosurg*. 1999;91(2)(suppl):151-156.
14. Isaacs RE, Podichetty VK, Sandhu FA, et al. Thoracic microendoscopic discectomy: a human cadaver study. *Spine (Phila Pa 1976)*. 2005;30(10):1226-1231.
15. Perez-Cruet MJ, Kim BS, Sandhu F, Samartzis D, Fessler RG. Thoracic microendoscopic discectomy. *J Neurosurg Spine*. 2004;1(1):58-63.
16. Khoo LT, Fessler RG. Microendoscopic decompressive laminotomy for the treatment of lumbar stenosis. *Neurosurgery*. 2002;51(5)(suppl):S146-S154.
17. Perez-Cruet MJ, Foley KT, Isaacs RE, et al. Microendoscopic lumbar discectomy: technical note. *Neurosurgery*. 2002;51(5)(suppl):S129-S136.
18. Fessler RG. Minimally invasive percutaneous posterior lumbar interbody fusion. *Neurosurgery*. 2003;52(6):1512.
19. Isaacs RE, Podichetty VK, Santiago P, et al. Minimally invasive microendoscopy-assisted transforaminal lumbar interbody fusion with instrumentation. *J Neurosurg Spine*. 2005;3(2):98-105.
20. Le H, Sandhu FA, Fessler RG. Clinical outcomes after minimal-access surgery for recurrent lumbar disc herniation. *Neurosurg Focus*. 2003;15(3):E12.
21. Chi JH, Dhall SS, Kanter AS, Mummaneni PV. The Mini-Open transpedicular thoracic discectomy: surgical technique and assessment. *Neurosurg Focus*. 2008;25(2):E5.
22. Oskouian RJ, Johnson JP. Endoscopic thoracic microdiscectomy. *Neurosurg Focus*. 2005;18(3):e11.
23. Regan JJ, Mack ML, Picetti GDI, Guyer RD, Hockshuler SH, Rashbaum RE. A comparison of video-assisted thoracoscopic surgery (VATS) with open thoracotomy in thoracic spinal surgery. *Today's Ther Trends*. 1994;11:203-218.
24. Rosenthal D, Dickman CA. Thoracoscopic microsurgical excision of herniated thoracic discs. *J Neurosurg*. 1998;89(2):224-235.
25. Stillerman CB, Chen TC, Couldwell WT, Zhang W, Weiss MH. Experience in the surgical management of 82 symptomatic herniated thoracic discs and review of the literature. *J Neurosurg*. 1998;88(4):623-633.

Manual Aspiration Technique to Retrieve a Prematurely Detached Coil During Cerebral Aneurysm Embolization

David A. Stidd, MD, MS;
Andrew K. Johnson, MD;
Demetrius K. Lopes, MD

References

1. Murayama Y, Nien YL, Duckwiler G, et al. Guglielmi detachable coil embolization of cerebral aneurysms: 11 years' experience. *J Neurosurg*. 2003;98(5):959-966.
2. Cognard C, Weill A, Castaings L, Rey A, Moret J. Intracranial berry aneurysms: angiographic and clinical results after endovascular treatment. *Radiology*. 1998;206(2):499-510.
3. Derdeyn CP, Cross DT III, Moran CJ, et al. Postprocedure ischemic events after treatment of intracranial aneurysms with Guglielmi detachable coils. *J Neurosurg*. 2002;96(5):837-843.
4. Eddleman CS, Welch BG, Vance AZ, et al. Endovascular coils: properties, technical complications and salvage techniques. *J Neurointerv Surg*. 2013;5(2):104-109.
5. Chung J, Kim YB, Hong CK, Joo JY, Shin YS, Lim YC. Stent salvage using the Enterprise stent for procedure-related complication during coil embolization of ruptured intracranial aneurysms. *Acta Neurochir (Wien)*. 2013;155(2):223-229.
6. Luo CB, Chang FC, Teng MM, Guo WY, Chang CY. Stent management of coil herniation in embolization of internal carotid aneurysms. *AJNR Am J Neuroradiol*. 2008;29(10):1951-1955.
7. Schutz A, Solymosi L, Vince GH, Bendszus M. Proximal stent fixation of fractured coils: technical note. *Neuroradiology*. 2005;47(11):874-878.
8. Wong GKC, Yu SCH, Wong K-T, Poon W-S. Stent salvage for parent vessel coil herniation during intracranial aneurysm embolization. *Surgical Practice*. 2009;13(4):114-118.
9. Sugiu K, Martin JB, Jean B, Rufenacht DA. Rescue balloon procedure for an emergency situation during coil embolization for cerebral aneurysms: technical note. *J Neurosurg*. 2002;96(2):373-376.
10. Lampmann LE, Sluzewski M, Van Rooij WJ. Retrieval of malpositioned, dislocated or fractured Guglielmi detachable coils from intracranial vessels: a report of seven cases. *Interv Neuroradiol*. 2000;6(3):251-256.
11. Koseoglu K, Parildar M, Oran I, Memis A. Retrieval of intravascular foreign bodies with goose neck snare. *Eur J Radiol*. 2004;49(3):281-285.
12. Henkes H, Lowens S, Preiss H, Reinartz J, Miloslavski E, Kuhne D. A new device for endovascular coil retrieval from intracranial vessels: alligator retrieval device. *AJNR Am J Neuroradiol*. 2006;27(2):327-329.
13. Dinc H, Kuzeyli K, Kosucu P, Sari A, Cekirge S. Retrieval of prolapsed coils during endovascular treatment of cerebral aneurysms. *Neuroradiology*. 2006;48(4):269-272.
14. Kung DK, Abel TJ, Madhavan KH, et al. Treatment of endovascular coil and stent migration using the Merci Retriever: report of three cases. *Case Rep Med*. 2012;2012:242101.
15. O'Hare A, Brennan P, Thornton J. Retrieval of a migrated coil using an X6 MERCI device. *Interv Neuroradiol*. 2009;15(1):99-102.
16. Vora N, Thomas A, Germanwala A, Jovin T, Horowitz M. Retrieval of a displaced detachable coil and intracranial stent with an L5 Merci Retriever during endovascular embolization of an intracranial aneurysm. *J Neuroimaging*. 2008;18(1):81-84.
17. Hopf-Jensen S, Hensler HM, Preiss M, Muller-Hulsbeck S. Solitaire® stent for endovascular coil retrieval. *J Clin Neurosci*. 2013;20(6):884-886.
18. Leslie-Mazwi TM, Heddier M, Nordmeyer H, et al. Stent retriever use for retrieval of displaced microcoils: a consecutive case series. *AJNR Am J Neuroradiol*. 2013;34(10):1996-1999.
19. Heuer GG, Zaghoul KA, Roberts R, Stiefel MF, Storm PB. Successful microsurgical extraction of a migrated coil in a pediatric patient after failed endovascular closure of a Blalock-Taussig shunt: case report. *J Neurosurg*. 2007;106(2)(suppl):136-138.
20. Kojima T, Miyachi S, Negoro M, et al. Coil retrieval following embolization of cerebral aneurysms. *Interv Neuroradiol*. 2003;9(suppl 1):149-155.

21. Raftopoulos C, Goffette P, Billa RF, Mathurin P. Transvascular coil hooking procedure to retrieve an unraveled Guglielmi detachable coil: technical note. *Neurosurgery*. 2002;50(4):912-914, discussion 914-915.
22. Shin YS, Lee KC, Kim DI, Lee KS, Huh SK. Emergency surgical recanalisation of A1 segment occluded by a Guglielmi detachable coil. *J Clin Neurosci*. 2000;7(3):259-262.
23. Thornton J, Dovey Z, Alazzaz A, et al. Surgery following endovascular coiling of intracranial aneurysms. *Surg Neurol*. 2000;54(5):352-360.
24. Fiorella D, Albuquerque FC, Deshmukh VR, McDougall CG. Monorail snare technique for the recovery of stretched platinum coils: technical case report. *Neurosurgery*. 2005;57(1)(suppl):E210, discussion E210.
25. Standard SC, Chavis TD, Wakhloo AK, Ahuja A, Guterman LR, Hopkins LN. Retrieval of a Guglielmi detachable coil after unraveling and fracture: case report and experimental results. *Neurosurgery*. 1994;35(5):994-998, discussion 999.
26. Ng PP, Halbach VV, Caragine LP, Dowd CF, Higashida RT. Guglielmi detachable coil extraction: suction generated by pusher-wire withdrawal after coil detachment within an intracranial aneurysm. *AJNR Am J Neuroradiol*. 2003;24(5):982-984.

Diffusion Tensor Imaging of Parkinson Disease, Atypical Parkinsonism, and Essential Tremor

Janey Prodoehl, PhD; Hong Li, PhD;
Peggy J. Planetta, PhD; Christopher G. Goetz, MD;
Kathleen M. Shannon, MD; Ruth Tangonan;
Cynthia L. Comella, MD; Tanya Simuni, MD;
Xiaohong Joe Zhou, PhD; Sue Leurgans, PhD;
Daniel M. Corcos, PhD; David E. Vaillancourt, PhD

References

1. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. *Brain*. 2002;125(pt 4):861-870.
2. Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. *Brain*. 2004;127(8):1693-1705.
3. Lang AE, Mikulis D. A new sensitive imaging biomarker for Parkinson disease? *Neurology*. 2009;72(16):1374-1375.
4. Mahlkecht P, Hotter A, Hussl A, Esterhammer R, Schocke M, Seppi K. Significance of MRI in diagnosis and differential diagnosis of Parkinson's disease. *Neurodegener Dis*. 2010;7(5):300-318.
5. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. *Neurology*. 2009;72(16):1378-1384.
6. Zhan W, Kang GA, Glass GA, et al. Regional alterations of brain microstructure in Parkinson's disease using diffusion tensor imaging. *Mov Disord*. 2012;27(1):90-97.
7. Du G, Lewis MM, Styner M, et al. Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. *Mov Disord*. 2011;26(9):1627-1632.
8. Rolheiser TM, Fulton HG, Good KP, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease. *J Neurol*. 2011;258(7):1254-1260.
9. Péran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. *Brain*. 2010;133(1):3423-3433.
10. Nicoletti G, Manners D, Novellino F, et al. Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor. *Neurology*. 2010;74(12):988-994.
11. Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. *Neurology*. 2002;58(4):575-580.
12. Schocke MF, Seppi K, Esterhammer R, et al. Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. *Neuroimage*. 2004;21(4):1443-1451.
13. Köllensperger M, Seppi K, Liener C, et al. Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. *Mov Disord*. 2007;22(12):1771-1776.
14. Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. *Neurology*. 2003;60(6):922-927.
15. Nicoletti G, Tonon C, Lodi R, et al. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease. *Mov Disord*. 2008;23(16):2370-2376.
16. Tsukamoto K, Matsusue E, Kanasaki Y, et al. Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging. *Neuroradiology*. 2012;54(9):947-955.
17. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 1992. *Neurology*. 2001;57(10)(suppl 3):S34-S38.
18. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. *J Neurol Sci*. 1999;163(1):94-98.
19. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. *Neurology*. 1996;47(1):1-9.
20. Deuschl G, Bain P, Brin M; Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on Tremor. *Mov Disord*. 1998;13(suppl 3):2-23.
21. Hardman CD, Halliday GM, McRitchie DA, Cartwright HR, Morris JG. Progressive supranuclear palsy affects both the substantia nigra pars compacta and reticulata. *Exp Neurol*. 1997;144(1):183-192.

22. Poonawalla AH, Zhou XJ. Correction of eddy currents in EPI-based diffusion tensor imaging. *Proc Intl Soc Magn Reson Med.* 2001;9:736.
23. Vaillancourt DE, Spraker MB, Prodoehl J, Zhou XJ, Little DM. Effects of aging on the ventral and dorsal substantia nigra using diffusion tensor imaging. *Neurobiol Aging.* 2012;33(1):35-42.
24. Noll DC, Nishimura DG, Macovski A. Homodyne detection in magnetic resonance imaging. *IEEE Trans Med Imaging.* 1991;10(2):154-163.
25. Wakana S, Jiang H, Nagae-Poetscher LM, van Zijl PC, Mori S. Fiber tract-based atlas of human white matter anatomy. *Radiology.* 2004;230(1):77-87.
26. Bassler PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. *Biophys J.* 1994;66(1):259-267.
27. Hasan KM, Narayana PA. Retrospective measurement of the diffusion tensor eigenvalues from diffusion anisotropy and mean diffusivity in DTI. *Magn Reson Med.* 2006;56(1):130-137.
28. Axelrad JE, Louis ED, Honig LS, et al. Reduced Purkinje cell number in essential tremor: a postmortem study. *Arch Neurol.* 2008;65(1):101-107.
29. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain.* 1991;114(pt 5):2283-2301.
30. Dickson DW. Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration. *J Neurol.* 1999;246(suppl 2):I16-I15.
31. Tsuboi Y, Slowinski J, Josephs KA, Honer WG, Wszolek ZK, Dickson DW. Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. *Neurology.* 2003;60(11):1766-1769.
32. Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. *Mov Disord.* 1997;12(2):133-147.
33. Nicoletti G, Manners D, Novellino F, et al. Diffusion tensor MRI changes in cerebellar structures of patients with familial essential tremor. *Neurology.* 2010;74(12):988-994.
34. Zhou X, Obuchowski NA, McClish DK. *Statistical Methods in Diagnostic Medicine.* Chichester, UK: John Wiley & Sons; 2002.
35. Li J, Fine JP. ROC analysis with multiple classes and multiple tests: methodology and its application in microarray studies. *Biostatistics.* 2008;9(3):566-576.
36. Agresti A. *An Introduction to Categorical Data Analysis.* 2nd ed. Chichester, UK: John Wiley & Sons; 2007.
37. Louis ED, Faust PL, Vonsattel JP, et al. Neuropathological changes in essential tremor: 33 cases compared with 21 controls. *Brain.* 2007;130(pt 12):3297-3307.
38. Boska MD, Hasan KM, Kibuule D, et al. Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. *Neurobiol Dis.* 2007;26(3):590-596.
39. Yoshikawa K, Nakata Y, Yamada K, Nakagawa M. Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. *J Neurol Neurosurg Psychiatry.* 2004;75(3):481-484.
40. Ito M, Watanabe H, Kawai Y, et al. Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. *J Neurol Neurosurg Psychiatry.* 2007;78(7):722-728.
41. Mukherjee P, Miller JH, Shimony JS, et al. Diffusion-tensor MR imaging of gray and white matter development during normal human brain maturation. *AJNR Am J Neuroradiol.* 2002;23(9):1445-1456.
42. Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV. Diffusion tensor imaging of deep gray matter brain structures: effects of age and iron concentration. *Neurobiol Aging.* 2010;31(3):482-493.
43. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. *AJNR Am J Neuroradiol.* 2002;23(6):985-988.
44. Rizzo G, Martinelli P, Manners D, et al. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. *Brain.* 2008;131(pt 10):2690-2700.
45. Tang CC, Poston KL, Eckert T, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. *Lancet Neurol.* 2010;9(2):149-158.